TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF THE INDIA XEROSTOMIA THERAPEUTICS MARKET 12
1.4 LIMITATIONS 13
1.5 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 CURRENCY AND PRICING 17
2.5 DBMR TRIPOD DATA VALIDATION MODEL 18
2.6 MULTIVARIATE MODELLING 21
2.7 STAGES LIFELINE CURVE 21
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 22
2.9 DBMR MARKET POSITION GRID 23
2.10 MARKET END USER COVERAGE GRID 24
2.11 VENDOR SHARE ANALYSIS 25
2.12 SECONDARY SOURCES 26
2.13 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 29
4.1 PESTEL'S MODEL 30
4.2 PORTER'S 5 FORCES 31
4.3 GROWTH STRATEGIES ADOPTED BY THE KEY MARKET PLAYERS 32
5 EPIDEMIOLOGY 33
6 PIPELINE ANALYSIS 34
7 INDIA XEROSTOMIA THERAPEUTICS MARKET, REGULATIONS 35
8 MARKET OVERVIEW 37
8.1 DRIVERS 39
8.1.1 RISING USE OF CHEMOTHERAPY AND RADIOTHERAPY IN THE CANCER TREATMENT 39
8.1.2 GROWING PREVALENCE OF XEROSTOMIA 39
8.1.3 ADVANCEMENTS IN THE PHARMACEUTICAL RESEARCH AND DEVELOPMENT 40
8.1.4 INCREASING USAGE OF PRESCRIPTION MEDICINES 41
8.2 RESTRAINTS 41
8.2.1 HIGH COST ASSOCIATED WITH XEROSTOMIA TREATMENT 41
8.2.2 SIDE EFFECTS ASSOCIATED WITH XEROSTOMIA THERAPIES 42
8.3 OPPORTUNITIES 42
8.3.1 RISING PRODUCT COLLABORATIONS AND PARTNERSHIPS 42
8.3.2 RISING RESEARCH AND DEVELOPMENT ACTIVITIES FOR THE DEVELOPMENT OF NOVEL THERAPIES 43
8.4 CHALLENGES 43
8.4.1 LACK OF AWARENESS OF XEROSTOMIA 43
8.4.2 LACK OF TREATMENTS AVAILABLE FOR XEROSTOMIA 44
9 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY PRODUCT TYPE 45
9.1 OVERVIEW 46
9.2 SALIVA SUBSTITUTES 49
9.2.1 MOUTHWASH 50
9.2.2 TOOTHPASTE 50
9.2.3 DENTIFRICES 50
9.2.4 ARTIFICIAL SALIVA 50
9.2.4.1 ORAL SOLUTION 52
9.2.4.1.1 ORAL SPRAY 52
9.2.4.1.2 ORAL RINSE 52
9.2.4.1.3 OTHERS 52
9.2.4.2 GEL 52
9.2.4.3 LOZENGE 53
9.2.4.4 DISSOLVING TABLETS 53
9.2.4.5 SWABS 53
9.2.4.6 POWDER 53
9.2.4.7 AQUORAL 54
9.2.4.8 SALIVASURE 54
9.2.4.9 OASIS 54
9.2.4.10 CAPHOSOL 54
9.2.4.11 XYLIMELTS 54
9.2.4.12 OTHERS 54
9.2.5 OIL-BASED SALIVA SUBSTITUTES 54
9.2.6 SALIVARY STIMULANTS 54
9.2.7 CHEWING GUMS 55
9.3 DRUGS 55
9.3.1 CHOLINOMIMETIC DRUGS 56
9.3.1.1 PILOCARPINE 56
9.3.1.2 CEVIMELINE 56
9.3.1.3 ANETHOLETRITHIONE 56
9.3.2 YOHIMBINE 56
9.3.3 OTHERS 57
9.3.4 BRANDED 57
9.3.5 SIALOR 58
9.3.6 PILOCARPINE 58
9.3.7 SALAGEN 58
9.3.8 EXOVAC 58
9.3.9 OTHERS 58
9.3.10 GENERIC 58
9.4 SALIVARY PEN 58
9.5 OTHER 59
10 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY TYPE 60
10.1 OVERVIEW 61
10.2 TRUE XEROSTOMIA 64
10.3 PSEUDO XEROSTOMIA OR SYMPTOMATIC XEROSTOMIA 64
11 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY MODE OF PURCHASE 65
11.1 OVERVIEW 66
11.2 PRESCRIPTION (RX) 69
11.3 OVER THE COUNTER (OTC) 69
12 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY POPULATION TYPE 70
12.1 OVERVIEW 71
12.2 GERIATRIC 74
12.3 ADULTS 74
13 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY END USER 75
13.1 OVERVIEW 76
13.2 DENTAL CLINICS 79
13.3 HOSPITALS 79
13.4 SPECIALTY CLINICS 80
13.5 HOME CARE 80
14 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 81
14.1 OVERVIEW 82
14.2 RETAIL PHARMACIES 85
14.3 HOSPITAL PHARMACIES 85
14.4 ONLINE SALES 86
15 INDIA XEROSTOMIA THERAPEUTICS MARKET: COMPANY LANDSCAPE 87
15.1 COMPANY SHARE ANALYSIS: INDIA 87
16 SWOT ANALYSIS 88
17 COMPANY PROFILE 89
17.1 COLGATE-PALMOLIVE COMPANY. 89
17.1.1 COMPANY SNAPSHOT 89
17.1.2 REVENUE ANALYSIS 89
17.1.3 PRODUCT PORTFOLIO 90
17.1.4 RECENT DEVELOPMENTS 90
17.2 SUN PHARMACEUTICAL INDUSTRIES LTD. 91
17.2.1 COMPANY SNAPSHOT 91
17.2.2 REVENUE ANALYSIS 91
17.2.3 PRODUCT PORTFOLIO 92
17.2.4 RECENT DEVELOPMENTS 92
17.3 HALEON GROUP OF COMPANIES. 93
17.3.1 COMPANY SNAPSHOT 93
17.3.2 REVENUE ANALYSIS 93
17.3.3 PRODUCT PORTFOLIO 94
17.3.4 RECENT DEVELOPMENTS 94
17.4 3M 95
17.4.1 COMPANY SNAPSHOT 95
17.4.2 REVENUE ANALYSIS 95
17.4.3 PRODUCT PORTFOLIO 96
17.4.4 RECENT DEVELOPMENTS 96
17.5 ALISH LIFE SAVING IMPEX PRIVATE LIMITED. 97
17.5.1 COMPANY SNAPSHOT 97
17.5.2 PRODUCT PORTFOLIO 97
17.5.3 RECENT DEVELOPMENT 97
17.6 GC CORPORATION. 98
17.6.1 COMPANY SNAPSHOT 98
17.6.2 PRODUCT PORTFOLIO 98
17.6.3 RECENT DEVELOPMENT 98
17.7 ICPA HEALTH PRODUCTS LTD 99
17.7.1 COMPANY SNAPSHOT 99
17.7.2 PRODUCT PORTFOLIO 99
17.7.3 RECENT DEVELOPMENT 99
17.8 SALIWELL LTD. 100
17.8.1 COMPANY SNAPSHOT 100
17.8.2 PRODUCT PORTFOLIO 100
17.8.3 RECENT DEVELOPMENT 100
18 QUESTIONNAIRE 101
19 RELATED REPORTS 104

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.